miR Sentinel Prostate Cancer Test
Commercial- Indications
- Prostate cancer
Company intelligence / Profile preview
miR Scientific
Rensselaer, New York, United Statesmirnascientific.com ↗
- Ownership
- Private
- Employees
- ~41
- Development stage
- Commercial
01
Overview
miR Scientific’s lead product, the miR Sentinel™ Prostate Cancer Test—a urine-based liquid biopsy—has demonstrated high accuracy in detecting and classifying prostate cancer at the molecular level. The test received FDA Breakthrough Device Designation in October 2020. Clinical studies show it can stratify patients into no evidence of disease or low-, intermediate-, or high-risk categories using a proprietary algorithm analyzing sncRNAs from urinary exosomes. Published data support its ability to distinguish indolent from aggressive disease and reduce unnecessary invasive procedures.
- Therapeutic areas
- Oncology
- Modalities
- Diagnostic testLiquid biopsyRNA-based diagnostics
- Industry
- Molecular Diagnostics
02
Drug pipeline
1 assetBeyond the preview
Go deeper on miR Scientific.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR Scientific.